PainReform (PRFX) Competitors $1.43 +0.03 (+2.43%) As of 07/3/2025 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. BCDA, EQ, SNSE, LPTX, BTAI, XFOR, PHXM, CSCI, BCLI, and PHIOShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), Brainstorm Cell Therapeutics (BCLI), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors BioCardia Equillium Sensei Biotherapeutics Leap Therapeutics BioXcel Therapeutics X4 Pharmaceuticals PHAXIAM Therapeutics COSCIENS Biopharma Brainstorm Cell Therapeutics Phio Pharmaceuticals PainReform (NASDAQ:PRFX) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Do insiders & institutionals have more ownership in PRFX or BCDA? 37.3% of PainReform shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer PRFX or BCDA? In the previous week, BioCardia had 5 more articles in the media than PainReform. MarketBeat recorded 5 mentions for BioCardia and 0 mentions for PainReform. BioCardia's average media sentiment score of 1.77 beat PainReform's score of 0.00 indicating that BioCardia is being referred to more favorably in the news media. Company Overall Sentiment PainReform Neutral BioCardia Very Positive Which has stronger earnings and valuation, PRFX or BCDA? BioCardia has higher revenue and earnings than PainReform. BioCardia is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$14.59M-$147.33-0.01BioCardia$60K182.16-$7.95M-$2.33-0.91 Do analysts prefer PRFX or BCDA? BioCardia has a consensus price target of $25.00, suggesting a potential upside of 1,084.83%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than PainReform.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is PRFX or BCDA more profitable? PainReform's return on equity of 0.00% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A N/A N/A BioCardia N/A -30,792.60%-223.06% Which has more volatility & risk, PRFX or BCDA? PainReform has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. SummaryBioCardia beats PainReform on 10 of the 15 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-0.018.9827.5220.22Price / SalesN/A682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book0.694.588.045.67Net Income-$14.59M$31.34M$3.18B$249.13M7 Day Performance1.70%3.25%2.90%3.28%1 Month Performance-27.21%7.08%3.70%5.55%1 Year Performance-22.07%0.17%36.15%21.12% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform0.7532 of 5 stars$1.43+2.4%N/A-21.9%$2.82MN/A-0.014Gap UpBCDABioCardia3.9938 of 5 stars$1.95-9.3%$25.00+1,182.1%-29.4%$11.13M$60K-0.8440News CoveragePositive NewsInsider TradeGap UpEQEquillium1.8272 of 5 stars$0.32+1.7%$3.00+851.8%-50.6%$11.07M$41.10M-0.8140Gap UpSNSESensei Biotherapeutics4.2018 of 5 stars$8.58-1.2%$90.00+949.0%-27.1%$10.94MN/A-0.3740Gap DownLPTXLeap Therapeutics1.4353 of 5 stars$0.30+13.5%$3.38+1,036.7%-84.3%$10.84MN/A-0.1740BTAIBioXcel Therapeutics4.4092 of 5 stars$1.81+2.3%$42.60+2,253.6%-88.7%$10.72M$2.27M-0.1390Gap UpXFORX4 Pharmaceuticals4.6739 of 5 stars$1.90+3.8%$72.33+3,707.0%-88.4%$10.59M$2.56M0.8980News CoverageHigh Trading VolumePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CSCICOSCIENS BiopharmaN/A$3.40+1.8%N/AN/A$10.51M$9.59M-0.5920Gap DownBCLIBrainstorm Cell Therapeutics4.1161 of 5 stars$1.12+5.7%$30.00+2,578.6%-77.8%$10.43MN/A-0.3340Gap DownPHIOPhio Pharmaceuticals2.8184 of 5 stars$2.35+8.3%$14.00+495.7%-53.4%$10.41MN/A-0.3710 Related Companies and Tools Related Companies BCDA Competitors EQ Competitors SNSE Competitors LPTX Competitors BTAI Competitors XFOR Competitors PHXM Competitors CSCI Competitors BCLI Competitors PHIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts